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Introduction: Patients with systemic lupus erythematosus (SLE) have an abnormal population of neutrophils, called
low-density granulocytes (LDGs), that express the surface markers of mature neutrophils, yet their nuclear morphology
resembles an immature cell. Because a similar discrepancy in maturation status is observed in myelodysplasias, and
disruption of neutrophil development is frequently associated with genomic alterations, genomic DNA isolated from
autologous pairs of LDGs and normal-density neutrophils was compared for genomic changes.
Methods: Alterations in copy number and losses of heterozygosity (LOH) were detected by cytogenetic microarray
analysis. Microsatellite instability (MSI) was detected by capillary gel electrophoresis of fluorescently labeled PCR
products.
Results: Control neutrophils and normal-density SLE neutrophils had similar levels of copy number variations,
while the autologous SLE LDGs had an over twofold greater number of copy number alterations per genome. The
additional copy number alterations found in LDGs were prevalent in six of the thirteen SLE patients, and occurred
preferentially on chromosome 19, 17, 8, and X. These same SLE patients also displayed an increase in LOH. Several
SLE patients had a common LOH on chromosome 5q that includes several cytokine genes and a DNA repair
enzyme. In addition, three SLE patients displayed MSI. Two patients displayed MSI in greater than one marker, and
one patient had MSI and increased copy number alterations. No correlations between genomic instability and
immunosuppressive drugs, disease activity or disease manifestations were apparent.
Conclusions: The increased level of copy number alterations and LOH in the LDG samples relative to autologous
normal-density SLE neutrophils suggests somatic alterations that are consistent with DNA strand break repair, while
MSI suggests a replication error-prone status. Thus, the LDGs isolated have elevated levels of somatic alterations
that are consistent with genetic damage or genomic instability. This suggests that the LDGs in adult SLE patients
are derived from cell progenitors that are distinct from the autologous normal-density neutrophils, and may reflect
a role for genomic instability in the disease.Introduction
Systemic lupus erythematosus (SLE) is an autoimmune
disease of complex etiology. Intense and ongoing research
efforts into the genetics of SLE have greatly advanced our
understanding of the susceptibility to and development of
the disease [1,2]. More recently, research emphasis has* Correspondence: mfdenny@temple.edu
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stated.shifted toward the identification and characterization of
causative genetic alterations that convey the associated
risk linkages in human SLE [3], as well as mouse models
of disease [4]. As research into the genetics of SLE con-
tinues, and the resolution of analysis becomes more re-
fined, it is becoming increasingly apparent that many of
the identified susceptibility intervals provide a rather lim-
ited contribution to disease incidence when considered
individually [5]. As such, models of SLE development gen-
erally propose that in the majority of cases, it is the inher-
itance of a combination of multiple susceptibility intervals
that actually drives the development of disease in any onetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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intervals has also been proposed to influence the mani-
festations of the disease, such as time to onset, disease
progression and target organ involvement [8]. Despite
all of these advances that have established the role of gen-
etics in SLE, inheritance alone rarely accounts for the inci-
dence of SLE in an individual, suggesting that there are
additional influences that contribute to the disease.
Because SLE is typically characterized by the progressive
development of autoantibodies that recognize compo-
nents of the cell nucleus [9], it is frequently considered to
result from a disruption in the regulation of the adaptive
immune system [10]. However, recent evidence supports
additional contributions from components of the innate
immune system [11]. Research toward defining the im-
portance of additional cell lineages in the development
of SLE is ongoing, and alterations in granulocyte func-
tion have been identified in both pediatric and adult
SLE [12-15]. In this regard, an intriguing population of
abnormal granulocytes has been identified and isolated
from SLE patients [12-14,16,17]. These low-density granu-
locytes (LDGs) contribute the granulocyte signature ob-
served in gene expression arrays from the mononuclear
cell fraction of pediatric lupus patients [17]. In adults,
LDGs mediate enhanced proinflammatory and cytotoxic
responses compared to those of autologous normal-density
neutrophils [12,13]. These LDGs readily induce endothelial
cell death and spontaneously form neutrophil extracellular
traps (NETs) [12,13]. Despite these advances in our under-
standing of the function of LDGs, their developmental ori-
gins remain undefined. One model proposes that LDGs
arise as a consequence of in situ activation of normal neu-
trophils [15]. However, direct gene expression array ana-
lysis and bioinfomatic pathway comparisons between
autologous pairs of LDGs and normal-density neutrophils
isolated from SLE patients were not entirely consistent
with an in situ activation model [13]. The expression of
genes associated with mature neutrophils did not differ be-
tween the LDGs and autologous normal-density neutro-
phils, nonetheless genes related to azurophilic granules, as
well as cytoskeleton and adhesion molecules, were altered
[13]. Thus, mechanisms other than in situ activation may
contribute to the development of LDGs in SLE patients.
One such alternate mechanism for the production of
LDGs would be a disruption in granulocyte development.
While the initial characterizations of LDGs suggested that
they were immature granulocytes, based upon their lobu-
lated or ovoid nuclei [14,17], further characterization of
the surface molecule expression on LDGs revealed a profile
that is more consistent with a fully mature developmental
state [12,13]. This apparent inconsistency in maturation
phenotype has also been described in patients with myelo-
dysplasias [18]. While the genetics of SLE is a topic of
intense interest, the potential contributions of geneticinstability and somatic mutations in SLE have received far
less attention [19], in large part due to the difficulties asso-
ciated with clearly identifying altered cell lineages and ap-
plying techniques that are suitable for analysis [20-22].
Since we have previously developed techniques to isolate
highly enriched autologous pairs of normal-density neutro-
phils and LDGs from individual SLE patients [12,13], it
was now possible to apply genomic techniques currently
utilized in cancer research to examine SLE LDGs for evi-
dence of genomic instability [23]. We hypothesized that
the LDGs arise from a process that is similar to myelodys-
plasia, and therefore genomic alterations should exist be-
tween the autologous pairs of LDGs and normal-density
neutrophils isolated from individual SLE patients. We
report herein that there is clear evidence for genetic in-
stability within the LDG lineage in SLE patients, with
multiple types of genomic abnormalities detected in
some SLE patients.
Methods
Recruitment of SLE patients and healthy controls
The Institutional Review Boards at Temple University
and the University of Michigan approved this study. Sub-
jects gave informed consent in accordance with the Dec-
laration of Helsinki. Lupus patients fulfilled the revised
American College of Rheumatology criteria for SLE and
enrollment was open to all patients examined at the out-
patient rheumatology clinics at Temple University and the
University of Michigan [24]. Disease activity was assessed
by the SLE disease activity index (SLEDAI) [25]. Female
healthy controls were recruited by advertisement. Demo-
graphic and clinical information for the lupus patients en-
rolled in the study (including medications) were extracted
from patient charts.
Isolation of LDGs and neutrophils
LDGs and autologous neutrophils were isolated from the
blood of SLE patients as described previously [12,13].
Briefly, venous blood (approximately 60 ml) was collected
in heparinized tubes and separated by discontinuous dens-
ity gradient centrifugation using Ficoll-Hypaque. LDGs
were isolated from the PBMC layer by negative selection
of lymphocytes and monocytes using a panel of biotinyl-
ated antibodies recognizing CD3, CD7, CD19, CD56,
CD79b, CD86, MHC class II, and erythrophorin (Ancell,
Bayport, MN, USA). The labeled cells were depleted
using paramagnetic beads coupled with an anti-biotin
antibody and a magnetic column (Miltenyi, Bergisch
Gladbach, Germany). Normal density neutrophils were
recovered from the corresponding erythrocyte fraction
of the Ficoll-Hypaque gradient by dextran sedimentation
of erythrocytes and lysis of residual red blood cells [26].
The resultant cell purity of LDGs and autologous neutro-
phils exceeded 90% as assessed by flow cytometric analysis
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marker CD15 [12].
Isolation of genomic DNA
Purified LDGs and neutrophils (5 to 20 X 106) were incu-
bated at 65°C overnight in 0.4 ml of cell lysis buffer con-
taining proteinase K (100 mMTris, pH 8.0, 0.2% sodium
dodecyl sulfate, 5 mM EDTA, 200 mMNaCl, 0.4 mg pro-
teinase K/mL (Sigma-Aldrich, St Louis, MO, USA)) [27].
After cooling, denatured proteins were removed by phenol-
chloroform extraction, and the aqueous phase was col-
lected. Total nucleic acids were precipitated by addition of
an equal volume of isopropanol, and recovered by centrifu-
gation. The pellet was washed once in 70% ethanol, air-
dried, dissolved in water, and treated with DNAse-free
RNAse (Promega Madison, WI, USA) for 30 min at 37°C.
Purified genomic (g)DNA was precipitated by addition of
three volumes of ethanol, incubated at −20°C overnight, re-
covered by centrifugation, and the pellet stored in 70%
ethanol at −20°C. The purity and integrity of the gDNA
was assessed by agarose gel electrophoresis. All samples
of gDNA were free of residual RNA and displayed a sin-
gle band of greater the 24 kb (see Additional file 1).
Cytogenetic microarray analysis
Cytogenetic microarray analysis was performed by the
Cytogenetics and Chromosomal Microarray core at the
Fox Chase Cancer Center, using the Affymetrix 2.7 M
Cytogenetics array chip, and genomic alterations were
identified using Affymetrix Chromosome Analysis Suite
software (Version 2.1) (Affymetrix, Santa Clara, CA, USA).
This microarray chip evaluates genomic segments and sin-
gle nucleotide polymorphism (SNP) markers, thus it is
capable of simultaneously identifying both copy number
alterations, such as duplications and deletions, as well
as copy number-neutral losses of heterozygosity (LOH)
[28-31]. Copy number alterations that were at least 9 kb
in length and detected by a minimum of 10 consecutive
markers with 80% confidence were included. Copy num-
ber alterations that spanned the centromere were ex-
cluded. Likewise, since only female subjects were used in
this study, any interval that was localized to the Y chromo-
some was eliminated. Previously established and novel
genomic variations were included in the analysis in order
to distinguish inherited copy number variants from som-
atic alterations in the SLE patients. Each pair of SLE LDG
and neutrophil samples was processed and analyzed to-
gether to minimize variability. The SNP markers on the
microarray chip were also used to identify copy number-
neutral LOH. Intervals greater than 2 Mb in length and
detected with a minimum of 80% confidence were in-
cluded in the analysis. Regions of LOH were compared
between each SLE patient’s LDG and neutrophil samples
to identify constitutional LOH from somatic mutations.PCR analysis of JAK2V617F mutation and Flt3 alterations
Somatic mutations resulting in the conversion of wild-type
JAK2 to a dominant activated form (JAK2V617F) were
assessed in the pairs of LDGs and normal-density neutro-
phils by tetra-primer amplification refractory mutational
screening using established primers and PCR conditions
[32,33]. The JAK2V617F positive cell line HEL served as a
control. Flt3 mutation within the kinase domain activation
loop was also tested by PCR [34]. The introduction of an
aspartate at amino acid position 835 was examined by the
loss of an EcoRV restriction site encoded in Flt3 [35]. Flt3
internal tandem duplications in the juxtamembrane region
were evaluated by an alteration in the size of the PCR
amplicon in controls and SLE samples [35].
Microsatellite instability (MSI) assays
A total of six microsatellites were analyzed using
fluorescence-labeled PCR primers and capillary gel elec-
trophoresis. The primer sequences and PCR protocol
for five quasimonomorphic microsatellites (NR21, NR22,
NR24, BAT25 and BAT26) and one polymorphic micro-
satellite (BAT40) have been described previously [36-39].
PCR products for both the LDGs and autologous neutro-
phils were compared. MSI was determined based upon
differences in the main PCR product peak identified for
each amplicon from the autologous pairs of LDGs and
normal-density neutrophils for each SLE patient. A
sample of genomic DNA isolated from the replication
error-prone cell line Jurkat was amplified and analyzed
in parallel with each set of patient samples to confirm
the reproducibility of the MSI assay [40].
Statistical analysis
Because the distribution of copy number alterations is
noncontinuous, only nonparametric analysis could be
applied. Pairwise comparisons between autologous sets
of LDGs and normal-density neutrophils were performed
using Wilcoxon signed-rank test, with a one-tailed P
value <0.05 considered statistically significant.
Results
Copy number alterations are present in LDGs isolated
from human SLE patients
To determine whether the LDGs isolated from human SLE
patients have evidence of genomic instability, we applied
diagnostic techniques commonly utilized in cancer re-
search. DNA from thirteen female SLE patients was ana-
lyzed for genomic alterations, compared to DNA isolated
from the neutrophils of nine healthy female donors. Cyto-
genetic microarray analysis was used to identify copy num-
ber alterations (duplications and deletions), as well as copy
number-neutral LOH, in genomic DNA isolated from au-
tologous pairs of LDGs and normal-density neutrophils.
Autologous pairwise comparisons of the genomic profile of
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phils distinguish heritable copy number variations from
bona fide somatic mutations. A total of 69 copy number
variations were identified in healthy controls (n = 9), and
114 and 244 alterations, respectively, were detected in
normal-density neutrophils and LDG fractions isolated
from SLE patients (n = 13). This corresponded to an aver-
age of 7.67 chromosomal copy number variations per dip-
loid genome in control neutrophils, similar to the average
present in the SLE neutrophils value of 8.77 variations. In
sharp contrast, the autologous SLE LDGs had an average
of 18.77 variations per genome (Figure 1A). This increased
frequency of copy number alterations in the LDGs was








































Figure 1 LDGs isolated from SLE patients have greater levels of copy
autologous neutrophils. (A) Genomic DNA from nine healthy female don
analysis. Values are mean ± SEM. *Distribution differs significantly from auto
one-tailed, P <0.01. (B) The incidence of genomic duplications and deletion
controls and SLE patients, whereas the autologous LDGs had a significant i
one-tailed, P <0.01) and duplications (b) Wilcoxon signed-rank test, one-tail
each healthy control (open blue diamonds, n = 9), and autologous pairs of
indicated. LDG samples with 18 or more copy number variations were con
indicated by a solid black line for ΔCNVhi, and a dashed gray line for the Δ
SEM, standard error of the mean; SLE, systemic lupus erythematosus.duplications (Figure 1B). Thus, the LDGs have copy num-
ber alterations that are not present in autologous normal-
density neutrophils, consistent with genomic instability.
Closer inspection of the individual SLE sample pairs
revealed two distinct profiles for the copy number alter-
ations in the LDGs (Figure 1C). The majority of the alter-
ations were found in a subset of SLE patients. Because
healthy donors had an average of number of copy number
alterations of 7.67 ± 2.58 (mean ± standard deviation (SD)),
we considered a SLE LDG sample as ‘change in copy num-
ber variation high’ (ΔCNVhi) if it possessed a total number
of copy number alterations that exceeded four standard de-
viations above the mean number of sites present in control











number alterations relative to control neutrophils and
ors and thirteen SLE patients was analyzed by cytogenetic microarray
logous normal-density SLE neutrophils, Wilcoxon signed-rank test,
s was similar in the neutrophil samples isolated from the healthy
ncreases in the number of deletions (a) Wilcoxon signed-rank test,
ed, P <0.01). Values are mean ± SEM. (C) Copy number variations for
SLE neutrophils (open red squares) and LDGs (filled red squares) are
sidered ΔCNVhi. Autologous sample pairs for each SLE patient are
CNVneg. CNV, copy number variation; LDG, low-density granulocyte;
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Using this criterion, seven of the thirteen SLE samples had
levels of copy number variations in their LDGs that were
equivalent to autologous normal-density neutrophils and
healthy controls (see Additional file 2). The remaining six
SLE patient samples had levels of copy number alterations
in their LDG fraction that exceeded the benchmark of
eighteen (range 18 to 52). It was noteworthy that the level
of copy number alterations detected in the normal-density
neutrophils isolated from the ΔCNVhi subset of SLE pa-
tients was similar to healthy donors (Figure 1C). Therefore,
the changes in copy number seen in lupus were restricted
to the LDGs, with the corresponding normal-density neu-
trophils isolated from these SLE patients possessing similar
levels of copy number variations as healthy controls, or
samples from the ΔCNVneg SLE patients (Figure 1C).
Therefore, there was a marked increased frequency of
alterations in copy number alterations in six of the thirty
SLE samples, consistent with genomic instability.
Copy number alterations in LDGs are localized to
chromosomes and genomic intervals
The distribution of the alterations in copy number was
assessed to determine if they were evenly, or randomly,
distributed across the entire genome or preferentially
localized to particular chromosomes or genomic re-
gions. The chromosomal alterations in the LDGs were
most prominent on relatively few chromosomes, includ-
ing chromosomes 8, 17, 19 and X (Figure 2), consistent
with a nonrandom distribution profile. Because the size
of each individual chromosome varies, the frequency for
each chromosomal alteration was normalized for rela-
tive size. For example, while chromosome 1 had an ap-
parent increase in the number of genomic alterations in
LDGs, it was approximately equivalent to the predictedFigure 2 Selective distribution of acquired copy number variations in
variations in healthy controls (open blue bar), SLE neutrophils (open red ba
increase in copy number alterations located on chromosome 19 were dete
Mann-Whitney post hoc analysis, one-tailed, P <0.01). Trends for increases le
and X. CNV, copy number variation; LDG, low-density granulocyte; SLE, systvalue based upon random distribution after normalization
for the large size of chromosome 1. When adjusted for
chromosomal size, chromosome 19 had the greatest rela-
tive increase above the predicted incidence with over
five-fold more variations per sample than predicted by
the random normalized distribution (Figure 2). The X
chromosome harbored the highest average incidence of
variations with three copy number alterations per sam-
ple, but this corresponded to a relative increase in X
chromosome alterations of slightly greater than three-
fold above the predicted value. The frequency of copy
number variations on the remaining chromosomes was
similar among the healthy control neutrophils, and SLE
normal-density neutrophils and LDGs. Thus, the LDGs
displayed a marked increase in somatic alterations on
specific chromosomes when compared to either autolo-
gous normal-density neutrophils or healthy controls.
The genomic alterations were restricted to relatively few
genetic intervals on specific chromosomes. Of note, the
somatic alterations identified on chromosome 19 were de-
letions that clustered within four intervals (Figure 3). None
of these affected regions on chromosome 19 have been re-
corded in the Database of Genomic Variations, maintained
by the University of Toronto [41]. Three of the LDG-
specific chromosome 19 deletions included a loss of exon
3 of the MUC16 gene. MUC16 encodes the CA125 anti-
gen, a diagnostic marker in ovarian cancer screening and
recently reported to be altered in SLE patients, leading to
the inclusion of SLE as a confounder in interpretation of
CA125 screening [42]. A second interval of chromosome
19 deletions in LDGs was concentrated within a cluster of
zinc-finger transcription factors within 19p12 [43]. The
number of 19p12 deletions ranged from one to four, and
seven LDG samples had deletions in the intergenic regions




LDGs to specific chromosomes. The frequency of copy number
r) and autologous LDGs (filled red bar) are displayed. *Significant
cted in LDGs relative to control neutrophils (Kruskal-Wallis test with
vels of CNVs in the LDGs were also suggested for chromosomes 8, 17,
emic lupus erythematosus.
Figure 3 The copy number alterations on chromosome 19 are localized to particular intervals. Chromosome 19 is shown in detail, and
the relative locations of individual duplications (upward filled arrowheads) and deletions (downward open arrowheads) are indicated for each
healthy control sample (dashed blue line adjacent to ideogram), SLE neutrophil (dashed red line) and autologous LDG sample (solid red line).
CNVs in the LDGs were predominantly within regions in 19p13 encoding the MUC16 gene, intergenic intervals in 19p12 within a ZNF gene
cluster, 19q12-q13 containing several Pregnancy-specific glycoproteins, and 19q13.4 amid an miRNA cluster. CNV, copy number variation; LDG,
low-density granulocyte; miRNA, microRNA; SLE, systemic lupus erythematosus.
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of the thirteen LDG samples, but not in any of the nine
controls. Two additional sites of common LDG deletions
were found on 19q. One site was within the Pregnancy-
specific glycoprotein 1 gene cluster, and another was within
an miRNA-dense region [44]. Another noteworthy set of
alterations was identified on chromosome 17, in which
LDGs from two patients possessed a somatic duplication
of the retinoic-acid receptor alpha (not shown).
Copy number-neutral losses of heterozygosity (LOH) are
also present in LDGs isolated from human SLE patients
The Affymetrix 2.7 M cytogenetic microarray chip also
detects copy number-neutral LOH. While the sensitivity
of the chip for the detection of LOH is lower than that for
copy number alterations, it is sufficient to identify large-
scale LOH (>2 Mb). The overall level of heterozygosity at
the genomic, or individual chromosomal level, did not dif-
fer among control neutrophils, SLE normal-density neu-
trophils and autologous LDGs (not shown), suggesting
that uniparental disomy resulting from break-induced rep-
lication was not present in LDGs. Rather, the previously
identified ΔCNVhi SLE patients also had a higher inci-
dence of LOH, again consistent with accumulated somaticdamage (Figure 4A). A distinct region of LOH in 5q23.3-
5q31.1 was observed in four of thirteen SLE patients, but
not in any of the nine healthy controls (Figure 4B). The
affected 5q LOH interval harbors several cytokine genes
(including IL-3, IL-4, IL-5, IL-13, and CSF2), a gene as-
sociated with arthritis susceptibility (SLC22A4), a DNA
repair gene (RAD50), and a gene that promotes Type 1
interferon responses (IRF1) [45-50]. Of the four SLE
samples possessing a region of 5q LOH, two were con-
stitutive LOH from patients that did not display an
increase in copy number alterations, one had increased
copy number alterations, and one SLE sample had a
somatic 5q LOH restricted to the LDGs that was not
present in the autologous normal-density neutrophils.
Thus, using cytogenetic microarray analysis, we identi-
fied SLE patients with a propensity for genomic instabil-
ity that included copy number alterations and LOH,
consistent with repair of DNA strand breaks.
Activating mutations in JAK2 and Flt3 are not observed in
LDGs
Due to the genomic alterations within the LDGs iso-
lated from SLE patients, it is possible these cells also
possess specific genomic alterations that affect neutrophil
Figure 4 Losses of heterozygosity (LOH) in LDGs from SLE patients. (A) LOH are prevalent in the ΔCNVhi SLE patients. The mean ± SEM of
LOH >2 Mb for healthy controls (open blue bar, n = 9), SLE neutrophils (red open bar) and SLE LDGs (red filled bar). ΔCNVneg (n = 7) and ΔCNVhi
(n = 6) SLE patients are indicated by unhatched and black-hatched bars, respectively. *Differs significantly from autologous normal-density SLE
neutrophils, Wilcoxon signed-rank test, one-tailed, P <0.01. (B) A LOH at 5q23-q31 is observed in four SLE patient samples. The autologous pairs
of neutrophils and LDGs are indicated by the dashed red line and solid red line, respectively. The affected 3.5 Mb interval is expanded to show
the relative positions of genes indicated in the text, additional genes within the interval are not shown for the purposes of clarity. SLE patient 11
has a loss of heterozygosity that is restricted to the LDG sample. Refer to Additional file 5 information regarding SLE patients. Genomic positions
based upon Human Genome Assembly Build 36.3. CNV, copy number variation; LDG, low-density granulocyte; SEM, standard error of the mean;
SLE, systemic lupus erythematosus.
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with a somatic mutation in the JAK2 kinase [51]. JAK2
V617F displays constitutive activation that promotes the
expansion of the erythroid and myeloid compartments
[52]. The LDGs and autologous normal-density neutro-
phils isolated from SLE patients were examined for JAK2
V617F mutation by tetra-primer amplification refractory
mutation system (ARMS) assay (see Additional file 3).
None of the samples displayed the JAK2 mutation, indi-
cating that the LDGs did not possess the activated form of
the JAK2 kinase. In addition, mutations in the Flt3 recep-
tor kinase domain were examined by PCR [35]. An acti-
vating point mutation at D835 within the kinase domain
and internal tandem repeats of the juxtamembrane region
were assayed, but again none of the sample pairs displayed
either of these alterations (see Additional file 4). Thus,
while a subset of the LDGs has an increased frequency
of somatic errors including duplications, deletions, and
LOH, specific mutations in either the JAK2 kinase or Flt3
kinase that have been associated with myeloproliferative
disorders or acute myeloid leukemia were not detected.Microsatellite instability (MSI) is present in LDGs isolated
from human SLE patients
While the cytogenetic microarray assays are quite sensitive
for the detection of copy number alterations and LOH,
they are not designed to identify all types of genomic alter-
ations. MSI is frequently indicative of a defect in DNA
mismatch repair during replication, either through inherit-
ance of nonfunctional DNA repair genes or through som-
atic inactivation of repair genes within the cancer cell
progenitor [36]. Because the LDGs demonstrated genomic
alterations consistent with increased incidence of DNA
strand breaks, a set of six microsatellite markers was ana-
lyzed for evidence of instability as an indicator of replica-
tion error. This panel included five quasimonomorphic
mononucleotide microsatellites used in the diagnosis of
DNA replication error-prone tumors (BAT25, BAT26,
NR21, NR22, NR24), as well as a polymorphic microsatel-
lite (BAT40). The microsatellites were amplified using
fluorescently labeled PCR primers, and the sizes of the
amplicons were evaluated by capillary gel electrophoresis.
MSI in the SLE patients was evaluated by comparing the
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that of the autologous normal-density neutrophil. Three
SLE patients displayed clear size shifts in the main prod-
uct peak. In total, six microsatellites displayed instability,
with one patient having three unstable microsatellites, an-
other with two, and a third with a single unstable micro-
satellite (Figure 5). The SLE patient with three unstable
microsatellites was also ΔCNVhi and possessed an LDG-
restricted 5q LOH. The patient with one unstable micro-
satellite marker also had an accompanying 5q LOH. The
SLE patient with two unstable microsatellite markers was
ΔCNVneg without LOH. Thus, LDGs isolated from SLE
patients displayed MSI in addition to the copy number al-
terations and LOH identified by cytogenetic microarray
analysis, indicating that genomic alterations associated
with DNA strand breaks and replication error are present
in LDGs (see Additional file 5).
Discussion
We have found evidence for multiple forms of genomic
instability within an abnormal pool of neutrophils iso-
lated from human SLE patients. Cytogenetic microarray
analysis revealed genomic instability within the LDGs of
SLE patients (see Additional file 6). Of the thirteen pa-
tients analyzed, six had pronounced alterations in copy
number within their LDG fraction relative to autologous
normal-density neutrophils. This is consistent with re-
ports in patients with myelodysplastic syndromes, where
cytogenetic microarray analysis detects an increased fre-
quency of somatic duplications and deletions in myeloid
progenitors, particularly in cases where classical cytogenet-
ics is uninformative [53-58]. The copy number alterations
and LOH are consistent with an increase in DNA strand
break repair within the LDGs [59,60]. In addition, three of





















Figure 5 Microsatellite instability (MSI) in SLE LDGs. Representative
chromatographic traces for capillary gel electrophoresis analysis of
duplex PCR reactions for the quasimonomorphic BAT25 and NR22
microsatellites. The size of the BAT25 amplicon differs between an
autologous pair of SLE neutrophils (red line) and LDGs (blue line).
The NR22 product was scored as stable in this SLE patient since
the primary peak in the LDGs is the same size as the autologous
normal-density neutrophils. LDG, low-density granulocyte; SLE,
systemic lupus erythematosus.associated with replication error-prone cells [61,62]. Thus,
there was evidence for multiple types of DNA damage in
the LDGs consistent with genomic instability in SLE. It is
unlikely these genomic alterations occur secondary to in
situ activation of the LDGs, resulting in NETosis and ran-
dom damage of genomic DNA, which is subsequently de-
tected as a genomic alteration. This alternative mechanism
is not supported due to the presence of genomic alter-
ations beyond deletions. The cytogenetic microarrays iden-
tified significant increases in the levels of copy number
gains and LOH, and MSI was detected by an independent
assay technique. The extent and types of genomic alter-
ations that are found in the LDGs are not consistent with
detection of activation-induced damage. The notion that
genomic instability can be associated with SLE is supported
by several observations. SLE patients are at an increased
risk for certain cancers, including lymphomas and myeloid
leukemia, beyond that associated with drug therapy for the
disease [63,64]. Lymphoblastoid cell lines prepared from
a subset of pediatric SLE patients display an increased
susceptibility to irradiation-induced double-stranded DNA
breaks [21], an observation that is consistent with the al-
terations in copy number that are present in the LDGs.
The copy number alterations were selectively distributed
on chromosomes 19, 17, 8 and X, and the copy number al-
terations on chromosome 19 were clustered within a few
genomic intervals, consistent with a nonrandom pattern of
damage. In addition to the accumulated somatic copy
number alterations, these SLE patients also had an in-
creased frequency of LOH. Several patients had an LOH
that included several genes on chromosome 5q. This par-
ticular interval encodes several cytokines, the DNA repair
enzyme RAD50, and IRF1. The transcription factor IRF1
contributes to the development autoimmunity in animal
models [65-67], and loss of IRF1 tumor suppressor func-
tion has been proposed to promote myelodysplasias and
the development of myelodysplasia-associated autoimmun-
ity [49,50,68]. The region of LOH at chromosome 5q is
contained within a larger interval that is associated with a
distinct type myelodysplasia, 5q-syndrome [50,68,69]. 5q-
syndrome is distinguished from other myelodysplasias in
that it typically has a milder clinical course, infrequently
converts to acute myeloid leukemia, is more prevalent in
females, and is responsive to lenalidomide therapy [70,71].
While previous studies have examined the functional
differences between LDGs and autologous normal-density
neutrophils, their developmental basis remained unex-
plored. We examined a model in which the LDGs arise
from abnormal myeloid development in a manner resem-
bling myelodysplasia, thus the techniques relied on the
comparison of each patient’s LDGs to their autologous
normal-density neutrophils. This experimental design is
better suited for interpretation of data from individual
SLE patients, rather than from a pooled cohort of patients,
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from somatic alterations [72-74]. While the genomic tech-
niques utilized in this study are suitable for evaluation of
genome-wide alterations, they lack the necessary degree of
fine specificity required for an associated functional ana-
lysis. For example, the consequence of a copy number loss
within a heterozygous lupus susceptibility interval may de-
pend upon whether the wild-type or the risk allele was
lost. Thus, cytogenetic microarray analysis alone may not
be sufficient to establish the relationship between genomic
alterations and functional consequences. In addition,
the incidence of microsatellite instability is consistent
with the potential to accumulate point mutations that
cannot be detected by the genomic microarray. Analysis
of point mutations would necessitate the use of a next-
generation sequencing-based screening panel, or whole
exome sequencing. Although this study has focused on
abnormal neutrophil development, it is certainly feasible
to design related studies to examine genomic alterations
in other cell lineages, including isolated subsets of ab-
normal T- and B-lymphocytes. This genomic analysis
may provide similar insights into the role of genomic al-
terations in the development of autoimmunity as recently
described for autoimmune lymphoproliferative syndrome,
or ALPS [75-77].
The similarity between the alterations in myeloid de-
velopment in myelodysplasia and SLE has been reported
previously. Bone marrow biopsies from SLE patients re-
semble those from MDS patients diagnosed with refrac-
tory anemia, with abnormal regions of myeloid precursors
and alterations in neutrophil morphology [78,79], and the
diagnostic criteria for MDS exclude SLE as a cause of
observed cytopenia. Recent advances in myelodysplasia re-
search have identified several new genomic alterations
that may also be relevant to SLE. Genome-wide exome se-
quencing has revealed that patients with myelodysplasia
frequently harbor somatic mutations in proteins that form
the spliceosome complex [80,81], and these mutations are
strongly associated with the type of myelodysplasia and
long-term prognosis. The possibility that spliceosome pro-
teins may also be mutated in LDGs opens an exciting new
area for future research, and a more direct and detailed
analysis of specific spliceosome proteins in SLE seems
warranted. In addition to promoting abnormal immune
cell development, genetic alterations in the spliceosome
machinery may also lead to dysregulated expression of
autoantigens, and the subsequent development of auto-
immunity, a feature that has been associated with myeloid
leukemias.
The advances in the genetics of SLE are occurring in
conjunction with research defining a key role for exces-
sive activation of the Type 1 interferon pathway [2,82].
Type 1 interferons participate in anti-viral immune re-
sponses, and the relationship between Type 1 interferongene expression signature and the development of SLE
is observed in several mouse models and in many SLE
patients with active disease [17,83-88]. As such, genes
that regulate the expression of, or the response to, Type
1 interferons are frequently given high priority as candi-
date genes in genetic analysis [89-91]. While this strategy
has identified variants and haplotypes of signal transducer
and activator of transcription 4 (STAT4) and interferon
regulatory factor 5 (IRF5) [92,93], definitive associations
within other genetic intervals, including the prominent as-
sociation within the MHC locus [94-96], have yet to be
established through this candidate gene selection process.
Because the relative risk of disease that is associated with
any one interval in isolation, it is generally interpreted as
supportive evidence of the polygenetic nature of the dis-
ease. However, it is also possible that the variant that con-
veys the true lupus susceptibility within the interval may
not have been identified. Because the screening of can-
didate genes within the larger susceptibility intervals
generally focuses on genes associated with immune cell
function or inflammatory responses, a potential selection
bias may be introduced into the screening process.
Influences beyond genetics are also thought to be crit-
ical for the development of SLE. Despite the current
interest in genetics, the disease concordance in identical
twins is relatively low compared to other inherited dis-
eases. This is typically attributed to a role for environ-
mental influences in SLE, however, the exact nature of
the environmental factor that drives disease development
in a genetically susceptible individual remains unresolved.
Our results suggest that one of the as yet undefined envir-
onmental components may be related to developmental
alterations that are attributable to genetic instability or
DNA damage. Recent high-resolution mapping of the
MHC locus has identified a susceptibility interval that
includes the DNA repair gene MSH5, consistent with a
role for DNA damage and repair in the development of
SLE [94,97,98].
We have identified multiple types of genomic alter-
ations in LDGs isolated from human SLE patients (copy
number gains and losses, copy number-neutral LOH,
and MSI) and found that these alterations are clustered
on certain chromosomes in areas that are potentially
involved in granulocyte development and immune re-
sponse regulation. A recent study has found that SLE
patients have an increased risk of developing myelodys-
plastic disorders and myeloid leukemias [99]. One of the
implications of this research is that candidate genes re-
lated to DNA damage repair should be included in the
interpretation of genome-wide association studies, with
affected individuals harboring the susceptibility gene likely
displaying a mutator phenotype [100]. The use of cytogen-
etic approaches that have been instrumental in under-
standing the development of cancer may also be applicable
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guide the development of potential new therapeutic strat-
egies for controlling the disease and its manifestations. Al-
though the current emphasis for new chemotherapeutic
agents for the treatment of SLE is focused almost exclu-
sively on developing antagonists of cytokines and growth
factors that are associated with disease severity, this re-
search suggests a role for the use of anti-myelodysplastic
agents as well.Conclusions
The peripheral blood mononuclear cell fraction isolated
from patients with SLE contains a pool of low-density
granulocytes (LDGs). Previous studies have proposed
that these abnormal neutrophils are either immature
polymorphonuclear cells, or neutrophils that have been
activated in situ. However, since LDGs express surface
markers that are characteristic of a fully mature neutro-
phil, and have a gene expression profile that is not consist-
ent with marked activation, an alternative mechanism
likely mediates the presence of LDGs. Because LDGs re-
semble the abnormal neutrophils present in myelodyspla-
sias, we applied a genomic analysis approach that is more
commonly used in cancer research to determine whether
LDGs display evidence of genomic instability. Numerous
genomic alterations were identified in LDGs isolated from
SLE patients, including copy number alterations, losses of
heterozygosity, and microsatellite instability. Taken to-
gether, this supports a model whereby genomic damage
contributes to the development of an abnormal population
of neutrophils. Moreover, the presence of genomic in-
stability suggests a confounding factor in the interpret-
ation of genetic association studies. These findings also
suggest that therapeutic approaches designed to control
myelodysplasias may also be beneficial in SLE.Additional files
Additional file 1: Intact genomic DNA isolated from autologous
pairs of SLE neutrophils and LDGs. Genomic DNA isolated from SLE
normal density neutrophils (top) and LDGs (bottom), DNA is intact and
high quality (major band is >24 kb with no smearing or laddering). Yield
and quality of DNA from LDGs and autologous normal density
neutrophils is suitable for cytogenetic microarray analysis.
Additional file 2: Cytogenetic microarray results for the SLE
ΔCNVneg donor SLE6. Six copy number variations were detected in the
LDG sample (red line adjacent to ideogram) as well as the autologous
normal density neutrophils (blue line). These CNVs are single copy
alterations which were comprised of five deletions (red downward
triangles located at 2q, 5p, 14q, 17p and 21q) and one duplication (blue
upward triangle located at 10q). All CNVs were present in both the SLE
LDGs and the autologous neutrophil samples consistent with a pattern
of inheritance rather than somatic alterations due to DNA damage. This
patient was also negative for 5q LOH, MSI, JAK2 V617F somatic
mutations, and activating mutations in Flt3 kinase. See Additional file 5
for clinical information.Additional file 3: JAK2 V617F somatic mutation was not present in
SLE LDGs or normal density neutrophils. JAK2 V617F somatic
mutation is associated with myeloproliferative disorders, and promotes
clonotypic expansion from the altered progenitor. Tetra-primer ARMS
PCR primers designed to differentiate JAK2 V617F and wild-type JAK2
were used to examine LDGs and neutrophil samples from SLE patients,
identical results were observed with all 13 SLE patients, and all control
neutrophils. PCR products from the JAK2 V617F-positive erythroleukemic
cell line HEL, and the wild-type JAK2-expressing cell line Jurkat, were
included as reference standards.
Additional file 4: The receptor tyrosine kinase Flt3 did not have an
activating D835 mutation in LDGs or normal-density neutrophils.
Shown are LDG and neutrophil samples from two SLE patients, identical
results were observed with all 13 SLE patients as well as all control
neutrophils. EcoRV cut and uncut Flt3 PCR products from the
T-lymphocytic cell line Jurkat were included as a reference.
Additional file 5: Summary of patients, genomic alterations, and
clinical characteristics. Average age of the patients was 39.1 yr (range:
23 to 63). Average time from original diagnosis was 7.6 yr (range: 1 to
25). HCQ, hydroxychloroquine; MMF, mycophenolate; MTX, methotrexate;
Pred, prednisone; Im, imuran; Qui, quinacrine; ND, not determined.
Additional file 6: Copy number variations detected in SLE samples.
For each autologous pair of SLE neutrophils and LDGs, the type of CNV
(copy number gain or loss), the affected chromosome (Ch), the position
of the CNV start and stop, total size of CNV in kb, the number of
contiguous microarray markers detecting the CNV, and the confidence
are indicated.Abbreviations
ARMS: amplification refractory mutation system; CNV: copy number variation;
LDG: low-density granulocyte; LOH: loss of heterozygosity; MSI: microsatellite
instability; SLE: systemic lupus erythematosus.Competing interests
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